Managing the Complexity of Modern Sterile Product Developments
Feature
Article
Pharmaceutical TechnologyBio/Pharma Outsourcing Innovation, February 2024 eBook
Volume 2024 eBook
Issue 2
Pages: 4-8
Managing the intricacies of sterile product development is imperative for successful and compliant outcomes.
Blister packed medication in sterile hypodermic syringes | Image Credit - © kenwnj - © kenwnj - stock.adobe.com
In the dynamic landscape of pharmaceutical development, the management of modern sterile product developments has become an increasingly complex task, attributed to the evolving diversity of APIs. The landscape now encompasses a wide range of pharmaceutical entities, ranging from traditional small molecules to the forefront of biotechnological advancements including biologics (e.g., proteins, fusion proteins, bispecific antibodies, antibody-drug conjugates peptides, and nucleic acid-based therapeutics including oligonucleotides, RNA and DNA therapeutics, viral vectors, cell therapy, and more). Most of these later APIs are formulated as parenteral preparations, amplifying the unique multifaceted challenges associated in terms of formulation, manufacturing, administration, and regulatory considerations.
Read this article in Pharmaceutical Technology’s Bio/Pharma Outsourcing Innovation eBook.
About the authors
Andrea Allmendinger is chief science officer at ten23 health.
Hanns-Christian Mahler is chief executive officer at ten23 health.
Article details
Pharmaceutical Technology/Pharmaceutical Technology Europe Outsourcing Innovation eBook
Issue 2
February 2024
Pages: 4-8
Citation
When referring to this article, please cite it as Allmendinger, A; Mahler, H. Managing the Complexity of Modern Sterile Product Developments. Pharmaceutical Technology, Bio/Pharma Outsourcing Innovation eBook. February 2024.
Recent Videos
Industry Outlook 2025: Technology as a Supporting Element
Tariff Pause Reinforces Uncertainty Among Biopharma Professionals
Industry Outlook 2025: Talent Up for Grabs
INTERPHEX 2025: Preventing Spills in the Manufacturing Process
INTERPHEX 2025: ‘Breaking Up the Octopus’ of Single-Use Systems
INTERPHEX 2025: Advanced Flow Sensor Technologies Enable More Accurate Measurement
Industry Outlook 2025: Evolving Pipelines and Supply Chain
INTERPHEX 2025: Beta Bags and Sterile Manufacturing
INTERPHEX 2025: Continuous and Controlled Freeze-Drying
Behind the Headlines Episode 14–Investment Trends, Policy Realignments, and Vaccines
Related Content
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024Podcast
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Entering New Domains for 3D Printing of Drug Products
April 6th 2025Article
3D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
